Paoli, PA, Jan. 13, 2015 – Results of the study, MarginProbe device is able to reduce re-excision rate of breast conserving surgery in invasive and pre-invasive breast cancer independent from any patient or tumor-related factors, were presented as part of the general poster session at the recent San Antonio Breast Cancer Symposium (SABCS).
The study, which was conducted by surgeons J.U. Blohmer, J. Tanko, J. Groβ and R. Völker reports an analysis of MarginProbe’s effectiveness when used to examine excised breast tissue during a breast conserving surgery (BCS, also known as lumpectomy), as determined by repeat surgery (re-excision) rates. The device was routinely used in a series of 150 consecutive BCS cases, by 8 surgeons. The results of the study indicate a 51 percent reduction in re-excision rates when using MarginProbe. Data also indicates a reduction in re-excision rates in invasive cancers from 14.7 percent down to 1.5 percent.
“International research, that has been conducted utilizing MarginProbe as its focal point, continues to show consistency among findings,” said Dan Hashimshony PhD, CEO and founder of Dilon Devices. “Again we’re seeing re-excision reduction of greater than 50 percent. We are excited that the body of data continuous to expand, and provide credible findings that may help improve surgical outcomes for BCS patients.”
The MarginProbe device, which was applied to 150 lumpectomy specimens from consecutive patients treated with BCS during 2013, was compared to the re-excision rate of a historical group of 156 patients treated with BCS in a similar period in 2012 without the application of the device.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.
Dilon Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.dunemedical.com.